ESMO E-Learning: Renal Cell Cancer - Clinical Case Study 1 and 2
- To provide an update of available therapeutic options in renal cell cancer patients with perspective how to best incorporate innovative therapeutics into treatment algorithms.
- To summarise profile of toxicities of innovative therapeutics introduced in the management of renal cell cancer patients in the recent years through the presentation of patient case study.
- To enhance the clinical practice implementation of the recent ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up of renal cell carcinoma.
This presentation has been developed in order to discuss clinical practice perspective of the new ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of renal cell carcinoma (RCC). The activity consists of two patient cases: the first case describes the clinical scenario in a RCC patient with lung metastases and the second presents a patient with slow progressing disease.
Metastatic RCC has traditionally been associated with poor prognosis and limited effective treatments. In the multimodal treatment of metastatic RCC, cytoreductive nephrectomy became the standard of care. Therapeutic targeting in RCC has strong biologic rationale and lately, several agents have been developed that target Angiogenesis and the cellular growth pathways. The clinical benefits of multi-targeted agents compared with conventional cytokine therapy have been widely reported. Currently, six drugs are approved in advanced RCC: interleukin 2 (IL-2), interferon (IFN)-?, sorafenib, sunitinib, temsirolimus and bevacizumab in combination with IFN (IFN and bevacizumab are approved only in Europe). Recently, everolimus has been shown to be active in patients who failed Tyrosine kinase inhibitor. However, this drug is not yet approved.
These two clinical cases presented in this E-Learning module discuss factors that can determine adherence to therapy with multi-targeted agents, including strategies in the management of adverse events. The module presents evidence-based facts as of 2009 with further investigation needed to optimally use these agents for maximal clinical benefit.
This E-Learning module was published in 2009 and expired in 2011.
The author has received honoraria for speaking and/or consulting from Pfizer, Bayer Schering Pharma, Roche, GlaxoSmithKline and Novartis.